NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Ascending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68788-7332-01 | 68788-7332 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | March 12, 2019 | In Use | ||
68788-7332-03 | 68788-7332 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | March 12, 2019 | In Use | ||
68788-7332-06 | 68788-7332 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | March 12, 2019 | In Use | ||
68788-7332-09 | 68788-7332 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | March 12, 2019 | In Use | ||
70934-0318-03 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2019 | Oct. 31, 2024 | In Use |
70860-0210-51 | 70860-0210 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | March 13, 2019 | Sept. 30, 2024 | In Use | |
00310-1350-95 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | March 15, 2019 | In Use | |
72485-0202-90 | 72485-0202 | imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | March 15, 2019 | In Use | |
72485-0203-30 | 72485-0203 | imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | March 15, 2019 | In Use | |
55700-0733-21 | 55700-0733 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 15, 2019 | In Use |
Found 10,000 results in 8 milliseconds — Export these results